Respiratory Syncytial Virus Infections
Recent clinical, regulatory, research and industry developments relating to this disease.
Immune Response to Respiratory Viral Infections.
The burden of respiratory syncytial virus in adults: a systematic review and meta-analysis.
Innate Immune Evasion by Human Respiratory RNA Viruses.
Long-term expanding human airway organoids for disease modeling.
The Human Immune Response to Respiratory Syncytial Virus Infection.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 5 clinical trials expected to report results, the earliest in Q3 2026.
- Q3 2026A Phase 3, Randomized, Controlled, Observer Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety of a Single Dose of GSK's RSVPreF3 OA Investigational Vaccine in Chinese Adults 18-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease
- Q1 2027A Phase 2b, Non-randomized, Controlled, Open-label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvanted RSVPreF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 Years of Age)
- Q2 2027A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.
- Q3 2027Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
- Q4 2028A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.
Clinical MilestonesView all 10Hide
- 2026-06-23A Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract DiseaseResults posted
- 2026-04-16A Phase III Single-Arm Open-Label Study to Evaluate the Safety PK ADA and Anti RSV nAb Following Administration of 2 Doses of Nirsevimab Given 5 to 6 Months Apart in Infants With CHD, CLD, Immunocompromise, Down Syndrome, or Born Pre-Term in JapanResults posted
- 2026-03-20A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and AboveResults posted
- 2026-03-17A Phase 3b, Non-randomized, Open Label, Multi-country, Cohort Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) During Any Pregnancy Conceived Post Vaccination/ControlResults posted
- 2026-07-01A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.Results expected Q2 2027
- 2026-06-22A Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.Results expected Q4 2028
- 2026-05-27A Phase 3, Randomized, Controlled, Observer Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety of a Single Dose of GSK's RSVPreF3 OA Investigational Vaccine in Chinese Adults 18-59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseaseResults expected Q3 2026
- 2026-03-06A Phase 2b, Non-randomized, Controlled, Open-label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvanted RSVPreF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 Years of Age)Results expected Q1 2027
- 2026-02-09Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in ChildrenResults expected Q3 2027
- 2026-07-01ClinicalA Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Human Interferon α1b Inhaled Solution in the Treatment of Respiratory Syncytial Virus Lower Respiratory Tract Infection in Children.Results expected Q2 2027
- 2026-06-23ClinicalA Phase 3, Randomized, Placebo-controlled, Observer-blind Study in India to Evaluate Immune Response, Reactogenicity and Safety of a Single Intramuscular Dose of RSVPreF3 OA Investigational Vaccine When Administered to Older Adults >=60 Years of Age and Adults 50-59 Years of Age at Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract DiseaseResults posted
- 2026-06-22ClinicalA Randomized, Double-blind, Two-stage, Placebo-controlled Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of Ziresovir (AK0529) in Adult Patients at High Risk for Respiratory Syncytial Virus (RSV) Infection.Results expected Q4 2028
- 2026-05-27ClinicalA Phase 3, Randomized, Controlled, Observer Blind, Immuno-bridging Study to Evaluate Immunogenicity, Reactogenicity, Safety of a Single Dose of GSK's RSVPreF3 OA Investigational Vaccine in Chinese Adults 18-59 Years of Age at Increased Risk of Respiratory Syncytial Virus DiseaseResults expected Q3 2026
- 2026-04-16ClinicalA Phase III Single-Arm Open-Label Study to Evaluate the Safety PK ADA and Anti RSV nAb Following Administration of 2 Doses of Nirsevimab Given 5 to 6 Months Apart in Infants With CHD, CLD, Immunocompromise, Down Syndrome, or Born Pre-Term in JapanResults posted
- 2026-03-20ClinicalA Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and AboveResults posted
- 2026-03-17ClinicalA Phase 3b, Non-randomized, Open Label, Multi-country, Cohort Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies (RSV MAT-001, RSV MAT-004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) During Any Pregnancy Conceived Post Vaccination/ControlResults posted
- 2026-03-06ClinicalA Phase 2b, Non-randomized, Controlled, Open-label, Extension Study to Evaluate the Persistence of Immune Response of the Adjuvanted RSVPreF3 Vaccine and the Safety and Immunogenicity Following Revaccination in Lung and Kidney Transplant Recipients (>=18 Years of Age)Results expected Q1 2027
- 2026-02-09ClinicalAzithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in ChildrenResults expected Q3 2027
- 2025-12-14ClinicalA Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Monoclonal Antibody TNM001 Injection Against Respiratory Syncytial Virus in High-risk InfantsCompleted
Clinical trials
The current development programme across all trial phases.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Respiratory Syncytial Virus Infections2
- Respiratory Syncytial Virus, Human2
- Respiratory Tract Infections2
- Communicable Diseases1
- Cost of Illness1
- COVID-191
- Global Health1
- Immunity, Innate1
Leading journals6
- Influenza and other respiratory viruses2
- Clinical microbiology reviews1
- Epidemiology and infection1
- International journal of molecular sciences1
- Journal of innate immunity1
- mBio1
Leading researchers8
- Wang X2
- Ajami NJ1
- Amatngalim GD1
- Antunes KH1
- Baglivo F1
- Bancej C1
- Barr I1
- Bassat Q1
Affiliations (unnormalised)6
- Alkek Center for Metagenomics and Microbiome Research1
- Bambino Gesù Children's Hospital1
- Biodiscovery Research Institute1
- Biological Science Institute (ICB)1
- Center for Respiratory Diseases and Meningitis1
- Central Public Health Laboratory1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Respiratory syncytial virus infections are pneumovirus infections caused by respiratory syncytial viruses. They affect humans and cattle most commonly, and infections in goats and sheep have also been reported. The literature grounding emphasizes epidemiology and the burden of disease in young children and older adults.
The cause is infection with respiratory syncytial virus. The supplied grounding does not support additional etiologic causes beyond the viral agent itself.
The human immune response to RSV includes an early strong neutrophil response, mediated by interleukin-8, and dendritic cell migration to the lungs as antigen-presenting cells. This is followed by systemic T-cell lymphopenia and then a pulmonary CD8+ T-cell response that contributes to viral clearance. Humoral immunity to reinfection is incomplete, although RSV IgG and IgA are protective, and the virus is discussed in the context of innate immune evasion.
The literature grounding identifies young children and older adults, especially those aged 65 years and older, as groups with substantial disease burden. Seasonal patterns are also emphasized in the epidemiology literature, indicating that timing of circulation varies across months. No additional individual risk factors are supported by the supplied material.
The supplied grounding does not describe a specific standard treatment regimen for RSV infection. It indicates that prophylactic vaccines or effective antiviral treatments are not generally available or provide only limited protection, and it frames management at the level of prevention and control strategies informed by epidemiology. No drug-class treatment standard is supported here.
AI-generated summary grounded in MeSH and 5 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.